Compare Elutia, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 46 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.04
-87.00%
1.65
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Mar 2026)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.85%
0%
-1.85%
6 Months
95.32%
0%
95.32%
1 Year
-40.78%
0%
-40.78%
2 Years
-67.58%
0%
-67.58%
3 Years
-62.01%
0%
-62.01%
4 Years
-83.2%
0%
-83.2%
5 Years
-90.02%
0%
-90.02%
Elutia, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-15.04%
EBIT Growth (5y)
-16.59%
EBIT to Interest (avg)
-4.20
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
-0.67
Tax Ratio
0.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
45.44%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.65
EV to EBIT
-0.81
EV to EBITDA
-0.92
EV to Capital Employed
-15.54
EV to Sales
0.90
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-87.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 5 Schemes (3.46%)
Foreign Institutions
Held by 7 Foreign Institutions (0.34%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
3.10
3.30
-6.06%
Operating Profit (PBDIT) excl Other Income
-5.40
-5.50
1.82%
Interest
0.00
0.00
Exceptional Items
-2.30
-1.50
-53.33%
Consolidate Net Profit
-7.90
-6.50
-21.54%
Operating Profit Margin (Excl OI)
-1,843.90%
-1,678.70%
-16.52%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -6.06% vs 0.00% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -21.54% vs -1,525.00% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
12.30
14.50
-15.17%
Operating Profit (PBDIT) excl Other Income
-17.20
-18.30
6.01%
Interest
0.00
0.90
-100.00%
Exceptional Items
3.60
-26.20
113.74%
Consolidate Net Profit
-15.90
-45.30
64.90%
Operating Profit Margin (Excl OI)
-1,497.80%
-1,337.10%
-16.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -15.17% vs -41.30% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 64.90% vs -9.95% in Dec 2024
About Elutia, Inc. 
Elutia, Inc.
Pharmaceuticals & Biotechnology
Aziyo Biologics, Inc. is a commercial-stage regenerative medicine company. The Company is focused on the development of products for patients undergoing surgery, concentrating on patients receiving implantable medical devices. Its products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair and soft tissue reconstruction markets. The Company's products include CanGaroo, ProxiCor, Tyke, VasCure, FiberCel, ViBone, OsteGro V and SimpliDerm. The Company fulfill tissue processing contracts through its contract manufacturing services at its Richmond, California facility.
Company Coordinates 
Company Details
12510 PROSPERITY DRIVE, SUITE 370 , SILVER SPRING MD : 20904
Registrar Details






